A
Alcista
Alcista · 25%KOD
$6.12
Precio del escenario
$91.320
+1.753 (+1.92%)Al cierre
Loading chart…
- Máximo
- 94.730
- Apertura
- 89.650
- Precio medio ponderado por volumen
- 91.75
- Volumen
- 1.01M
- Capitalización
- 127.66M
- Mínimo
- 89.200
- Importe
- 92.71M
- EV/EBITDA, TTM
- 0.00
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.
Análisis de IA of Kodiak Sciences Inc (KOD)
ComprarKodiak Sciences Inc appears to be a good buy right now due to its recent successful drug trial results that led to a stock surge of over 177%, pushing the current price to $87.63. Additionally, the stock has shown a remarkable year-to-date change of +236.78%, reflecting strong investor interest and confidence in its future potential. However, a risk to consider is the negative earnings per share (EPS) forecast, with an EPS of -1.05 reported in the last earnings, indicating ongoing financial challenges.
Recomendaciones de analistas (1)
-69.49% Potencial de caída
Comprar
1 Comprar
0 Mantener
0 Vender
Actual: 91.32
Mínimo
14.00
Promedio
27.86
Máximo
50.00
H.C. Wainwright
Comprar
$126
2026-10-12
H.C. Wainwright
2026-10-12
Precio objetivo
$126
Comprar
Goldman Sachs
Neutral
$103
2026-09-29
Goldman Sachs
2026-09-29
Precio objetivo
$103
Neutral
UBS
Comprar
$120
2026-09-29
UBS
2026-09-29
Precio objetivo
$120
Comprar
Jefferies
Comprar
$112
2026-09-28
Jefferies
2026-09-28
Precio objetivo
$112
Comprar
LifeSci Capital
Superar al mercado
$145
2026-09-28
LifeSci Capital
2026-09-28
Precio objetivo
$145
Superar al mercado
Métricas de valoración
El PER previsto actual de Kodiak Sciences Inc (KOD) es 0.00, frente a su media de 5 años de -2.54.
Escenarios de precio de Alphio AI para KOD
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con KOD en cartera
Cronología de eventos
Noticias
8.510-07PRnewswireKodiak Sciences to Present Clinical Data at AAO 2026
8.510-07NewsfilterKodiak Sciences to Present Clinical Data at AAO 2026
2.010-01stocktwitsOCUL Stock Plummets 22% Amid Competitive Pressure
1.009-29stocktwitsTrump Hosts AI Leaders Amid Economic Indicators
7.509-29stocktwitsKOD Stock Soars 177% Following Successful Drug Trial Results
Preguntas frecuentes sobre KOD, respondidas por Alphio AI
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Kodiak Sciences Inc appears to be a good buy right now due to its recent successful drug trial results that led to a stock surge of over 177%, pushing the current price to $87.63. Additionally, the stock has shown a remarkable year-to-date change of +236.78%, reflecting strong investor interest and confidence in its future potential. However, a risk to consider is the negative earnings per share (EPS) forecast, with an EPS of -1.05 reported in the last earnings, indicating ongoing financial challenges.
1 analysts cover KOD: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 27.86.
Comunidad
Más ↗
$KOD Kodiak Sciences price target raised to $103 from $36 at Goldman Sachs Goldman Sachs analyst Andrea Newkirk raised the firm's price target on Kodiak Sciences to $103 from $36 and keeps a Neutral rating on the shares. The firm is citing the company's positive data from the Phase 3 DAYBREAK study evaluating Zenkuda and tabirafusp alfa tedromer against aflibercept 2mg Q8W in treatment-naive wet AMD patients, the analyst tells investors in a research note. Zenkuda achieved non-inferiority on both visual acuity and anatomical drying, but more importantly, demonstrated extended durability of effect with 54% of patients achieving Q24W dosing at the primary endpoint of 40-48 weeks, Goldman Sachs added.
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.